Aerospace and defense company Raytheon (NYSE: RTX) will be reporting earnings this Tuesday before market hours. Here’s what you need to know.
RTX beat analysts’ revenue expectations by 5.4% last quarter, reporting revenues of $22.48 billion, up 11.9% year on year. It was a stunning quarter for the company, with an impressive beat of analysts’ organic revenue estimates and a solid beat of analysts’ EBITDA estimates.
Is RTX a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, analysts are expecting RTX’s revenue to grow 4.7% year on year to $22.65 billion, slowing from the 9.1% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.47 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. RTX has a history of exceeding Wall Street’s expectations, beating revenue estimates every single time over the past two years by 3.4% on average.
Looking at RTX’s peers in the aerospace and defense segment, some have already reported their Q4 results, giving us a hint as to what we can expect. CACI delivered year-on-year revenue growth of 5.7%, missing analysts’ expectations by 2.4%, and AAR reported revenues up 15.9%, topping estimates by 4.4%. CACI traded up 3.6% following the results while AAR was also up 2.1%.
Read our full analysis of CACI’s results here and AAR’s results here.
There has been positive sentiment among investors in the aerospace and defense segment, with share prices up 9.2% on average over the last month. RTX is up 6.1% during the same time and is heading into earnings with an average analyst price target of $202.83 (compared to the current share price of $195.63).
P.S. STOP buying the AI stocks everyone's talking about. The real money? It’s in the profitable pick nobody’s watching yet. We’ve identified an AI profit machine that’s flying under Wall Street’s radar—for now. We can’t keep this research public forever—grab your FREE copy before we pull it offline. GO HERE NOW.
